Clinical trials: sponsored by The Netherlands Cancer Institute
Breast Cancer
Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
Triple negative breast cancer (TNBC) is a difficult to treat molecular subtype with a poor survival. TNBC can be divided into at least two molecular entities; BRCA-like and non-BRCA-like.
- Trial name
- Triple-B (NCT01898117)
- Testing
- Carbo/cyclo, Carbo/cyclo + atezolizumab, Paclitaxel
- Where
- 49 sites in Netherlands
- Volunteers
- 304 people
- Sponsor
- The Netherlands Cancer Institute
HER2-positive Breast Cancer
Basket Study for Oligo-metastatic Breast Cancer
The study will include patients with HER2-positive breast cancer and 1- 3 distant metastatic lesions, all amenable for curative intervention. Patients will be stratified by prior therapy and ER expression.
- Trial name
- ANISE (NCT05982678)
- Testing
- Trastuzumab deruxtecan
- Where
- Netherlands
- Volunteers
- 72 people
- Sponsor
- The Netherlands Cancer Institute
Laryngeal Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma
Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.
Rationale | Elective neck irradiation is performed in head and neck cancer patients treated with definitive (chemo)radiotherapy. The aim is to eradicate nodal metastases that are not detectable by pretreatment imaging techniques.
- Conditions
- Laryngeal Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
- Trial name
- PRIMO (NCT05333523)
- Testing
- Sentinel lymph node biopsy guided selective elective neck irradiation, Standard elective neck irradiation
- Where
- 9 sites in Netherlands
- Volunteers
- 242 people
- Sponsor
- Radboud University Medical Center
Glottis Tumor, Larynx Cancer
VoiceS: Voice Quality After Transoral CO2-Laser Surgery Versus Single Vocal Cord Irradiation for Larynx Cancer
Laser surgery and radiotherapy are well-established standards of care for unilateral stage 0 \& I carcinoma in situ (Cais) and squamous cell carcinoma of glottic larynx (SCCGL).
- Trial name
- VoiceS (NCT04057209)
- Testing
- Single Vocal Cord Irradiation (SVCI), Arm A: Transoral CO2-Laser Microsurgical Cordectomy (TLM)
- Where
- 4 sites in France, India and 1 more
- Volunteers
- 34 people
- Sponsor
- Olgun Elicin
Non Small Cell Lung Cancer Stage III, Immunotherapy
Response and Toxicity Prediction by Microbiome Analysis After (Concurrent) Chemoradiotherapy
The predictive value of the microbiome (throat swabs, stool and of bronchial samples) to identify patients who will relapse during durvalumab treatment after CRT (False negative Rate) at 6 months.
- Trial name
- Prediction (NCT04711330)
- Where
- 6 sites in Belgium, Netherlands
- Volunteers
- 126 people
- Sponsor
- Leiden University Medical Center
Renal Cell Carcinoma
Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer
The NESCIO-trial is a multicenter, randomized, open-label, three-arm phase II trial investigating different combinations of neoadjuvant immunotherapy in patients with primary, resectable, intermediate to high-risk, clear-cell…
- Trial name
- NESCIO (NCT05148546)
- Testing
- Neoadjuvant nivolumab, Neoadjuvant ipilimumab, Neoadjuvant relatlimab
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 69 people
- Sponsor
- The Netherlands Cancer Institute
Testicular Cancer
TACkLE Study - Tackling Adverse Chemotherapy-associated Late Effects
Testicular cancer (TC) is a rare disease, which mostly affects young men aged 15-35 years. Their life expectancy has greatly improved due to the introduction of platinum-containing chemotherapy for disseminated TC in the late…
- Trial name
- TACkLE (NCT02276430)
- Testing
- Vena punction
- Where
- 3 sites in Netherlands
- Volunteers
- 939 people
- Sponsor
- University Medical Center Groningen
Colorectal Cancer Metastatic
LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)
Part I of this study is designed to identify the recommended phase 2 dose (RP2D) of the combination regimen of LY3200882/capecitabine as second line treatment in patients with 5-FU or capecitabine resistant CRC.
- Trial name
- NCT04031872
- Testing
- LY3200882
- Sponsor
- The Netherlands Cancer Institute
Liver Metastases
Functional Liver After SBRT
In this study, the investigators aim to determine the dose-effect relationship between radiation dose and liver function by performing a hepatobiliary scintigraphy (HEBIS) before and after stereotactic body radiotherapy (SBRT)…
- Trial name
- FAFOR (NCT07033364)
- Testing
- Functional liver imaging using hepatobiliary scintigraphy (HEBIS)
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- The Netherlands Cancer Institute
Cervical Cancer
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
This study will include patients with invasive cervical cancer that wish to keep their fertility as much as possible in the future after treatment.
- Trial name
- NCT04016389
- Testing
- Cisplatin, Carboplatin, Paclitaxel
- Where
- 4 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- University Health Network, Toronto
Cutaneous Squamous Cell Carcinoma
Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery
To determine the histopathological response rate to neo-adjuvant nivolumab and nivolumab plus ipilimumab at time of standard of care(surgery ± radiotherapy).in patients with cutaneous squamous cell carcinoma.
- Trial name
- MATISSE (NCT04620200)
- Testing
- Nivolumab, Ipilimumab
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- The Netherlands Cancer Institute
Early-onset Colorectal Cancer
Earlier Detection and Optimization of Treatment and Prognosis for Patients With Early-onset Colorectal Cancer
The study aims to collect high quality clinical data on lifestyle and patient biomaterials prior to start or during / after treatment of early-onset colorectal cancer (EOCRC) and to inform on treatment and survival outcomes of…
- Trial name
- BIO-EOCRC (NCT06568679)
- Testing
- No intervention; observational
- Where
- Netherlands
- Volunteers
- 300 people
- Sponsor
- The Netherlands Cancer Institute
Colon Cancer
Vinorelbine in Advanced BRAF-like Colon Cancer
Vecchione et al showed that suppression of RANBP2 results in mitotic defects only in BRAF-like colon cancer (CC) cells, which leads to cell death.
- Trial name
- EORTC1616 (NCT03482362)
- Testing
- Vinorelbine Tartrate
- Where
- Netherlands
- Volunteers
- 1 people
- Sponsor
- The Netherlands Cancer Institute
Drug Safety Biomarkers
Food-effect Study on Uracil and Dihydrouracil Levels as a Diagnostic Marker of Dihydropyrimidine Dehydrogenase Activity
Healthy volunteer food-effect study to determine the effect of food on uracil and dihydrouracil levels in plasma
- Trial name
- NCT02718664
- Testing
- Test meal (breakfast)
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- The Netherlands Cancer Institute
Brain Metastases
Automated Detection of Brain Metastases on MRI
This reader study aims at assessing whether the radiologist aided with AI software has at least a non-inferior performance than without AI assistance in detecting brain metastases.
- Trial name
- BrainMets AI (NCT06727032)
- Testing
- Brain Metastasis AI
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Robovision BV
Prostate Cancer, Cervical Cancer
Feasibility of CBCT-Guided Online Adaptive Radiotherapy (FASCINATE)
The accuracy of radiotherapy can be increased by correcting for geometric uncertainties and changes between radiotherapy fractions.
- Conditions
- Prostate Cancer, Cervical Cancer, Bladder Cancer, Lung Cancer
- Trial name
- FASCINATE (NCT06691776)
- Testing
- online CBCT-guided adaptive radiation therapy using a new software
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- The Netherlands Cancer Institute
FIGO Stage III Ovarian Cancer, Peritoneal Cancer
Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer
Cytoreductive surgery (CRS) with the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) is used in current clinical practice in selected patients with advanced ovarian cancer.
- Conditions
- FIGO Stage III Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Carcinoma
- Trial name
- CisCon (NCT05406674)
- Testing
- Cisplatin 100 mg/m2, Cisplatin 40 mg/l
- Where
- 2 sites in Netherlands
- Volunteers
- 40 people
- Sponsor
- The Netherlands Cancer Institute
Stomach Neoplasm, Peritoneal Carcinomatosis
Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.
A randomized controlled two-armed phase III trial for gastric cancer patients with peritoneal dissemination. Randomization between gastrectomy + cytoreductive surgery + HIPEC (experimental arm) and palliative systemic…
- Trial name
- PERISCOPEII (NCT03348150)
- Testing
- Cytoreductive surgery + Gastrecomy, Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- Where
- Netherlands
- Volunteers
- 102 people
- Sponsor
- The Netherlands Cancer Institute
Kidney Cancer, Renal Neoplasms
Tumor Rupture During Robotic Partial Nephrectomy
The RUPTURE Project is a multi-center observational study aiming to understand tumor rupture during robotic partial nephrectomy (RAPN), a minimally invasive surgery used to treat kidney tumors.
- Trial name
- RUPTURE (NCT07065825)
- Testing
- robot-assisted partial nephrectomy
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Melanoma, Skin Neoplasms
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma
This is a mono-center open-label proof-of-concept pharmacologic study to explore the efficacy and safety of vorinostat in advanced BRAF mutated melanoma, which became resistant for BRAF-inhibitors or the combination of BRAF- and…
- Trial name
- NCT02836548
- Testing
- Vorinostat
- Where
- Netherlands
- Volunteers
- 33 people
- Sponsor
- The Netherlands Cancer Institute